250 related articles for article (PubMed ID: 12702739)
1. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
2. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L; Delmas P; Abogadie FC; Brown DA
J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
[TBL] [Abstract][Full Text] [Related]
3. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
4. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
[TBL] [Abstract][Full Text] [Related]
5. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C; Netzer R
Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
[TBL] [Abstract][Full Text] [Related]
6. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
7. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.
Martire M; Castaldo P; D'Amico M; Preziosi P; Annunziato L; Taglialatela M
J Neurosci; 2004 Jan; 24(3):592-7. PubMed ID: 14736843
[TBL] [Abstract][Full Text] [Related]
8. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying modulation of neuronal KCNQ2/KCNQ3 potassium channels by extracellular protons.
Prole DL; Lima PA; Marrion NV
J Gen Physiol; 2003 Dec; 122(6):775-93. PubMed ID: 14638935
[TBL] [Abstract][Full Text] [Related]
10. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
11. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
Punke MA; Friederich P
Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
[TBL] [Abstract][Full Text] [Related]
12. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
Wickenden AD; Zou A; Wagoner PK; Jegla T
Br J Pharmacol; 2001 Jan; 132(2):381-4. PubMed ID: 11159685
[TBL] [Abstract][Full Text] [Related]
13. Properties of single M-type KCNQ2/KCNQ3 potassium channels expressed in mammalian cells.
Selyanko AA; Hadley JK; Brown DA
J Physiol; 2001 Jul; 534(Pt 1):15-24. PubMed ID: 11432988
[TBL] [Abstract][Full Text] [Related]
14. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
15. Single-channel analysis of KCNQ K+ channels reveals the mechanism of augmentation by a cysteine-modifying reagent.
Li Y; Gamper N; Shapiro MS
J Neurosci; 2004 Jun; 24(22):5079-90. PubMed ID: 15175377
[TBL] [Abstract][Full Text] [Related]
16. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels.
Kim RY; Pless SA; Kurata HT
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9702-E9711. PubMed ID: 29078287
[TBL] [Abstract][Full Text] [Related]
17. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
[TBL] [Abstract][Full Text] [Related]
18. Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels.
Hadley JK; Noda M; Selyanko AA; Wood IC; Abogadie FC; Brown DA
Br J Pharmacol; 2000 Feb; 129(3):413-5. PubMed ID: 10711337
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.
Hu HN; Zhou PZ; Chen F; Li M; Nan FJ; Gao ZB
Acta Pharmacol Sin; 2013 Oct; 34(10):1359-66. PubMed ID: 23933653
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
